Last reviewed · How we verify

NCT06665711

Comparison of 3% Hypertonic Saline and Salbutamol in Children With Bronchiolitis

Not yet recruiting NA Last updated 30 October 2024
What this trial tests

NA trial testing 3% Hypertonic Saline in BRONCHIOLITIS in 100 participants. Not yet recruiting.

Timeline
3 December 2024
Primary endpoint
6 February 2025
10 March 2025

Quick facts

Lead sponsorUniversity of Health Sciences Lahore
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date3 December 2024
Primary completion6 February 2025
Estimated completion10 March 2025

Drugs / interventions tested

Conditions studied

Sponsor

University of Health Sciences Lahore

Who can join

Adults 2 Months to 24 Months, any sex, with BRONCHIOLITIS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bronchiolitis is a common lower respiratory tract infection that often leads to hospitalization in infants. The use of nebulized 3% hypertonic saline for treating bronchiolitis is being explored as an alternative to Salbutamol. In nebulizers, normal saline serves as a diluent, allowing water molecules or drugs to be inhaled into the lungs. However, there has been limited research on this topic, and no local trials have been conducted. This study aims to compare the effectiveness of 3% hypertonic saline and Salbutamol in treating bronchiolitis. A randomized controlled trial will be conducted at the Department of Pediatric Medicine, Services Institute of Medical Sciences, Lahore, over one year, involving 100 infants divided into two groups: one receiving 3% hypertonic saline and the other receiving Salbutamol. The RDAI score will be evaluated before and during treatment to assess recovery time. Data will be collected using a proforma and analyzed with SPSS v25. The study aims to determine which treatment leads to faster symptom control and shorter hospital stays, with significance defined as a p-value ≤0.05. The findings will guide future treatment choices for infants with bronchiolitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of 3% Hypertonic Saline

Trials testing the same drug.

Other University of Health Sciences Lahore trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06665711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing